iSTAR Medical is a medtech company developing minimally invasive ophthalmic implants for the treatment of patients with glaucoma. MINIjectTM, made of STAR® material, is iSTAR Medical’s revolutionary microinvasive glaucoma surgery (MIGS) device for patients with primary open-angle glaucoma. iSTAR Medical was founded in 2011 and is headquartered in Wavre, Belgium.
iSTAR Medical has developed MINIject using the innovative STAR® material, created by the University of Washington, Seattle (USA). MINIject is designed to powerfully reduce IOP (intraocular pressure) by enhancing aqueous humour outflow from the anterior chamber to the supraciliary space of the eye, and to sustain these results over time. Clinical trials show that IOP is reduced by over 40% to a mean of 13.8 mmHg at two years post-surgery. MINIject exhibits all the advantages of the STAR® material such that it conforms to the eye anatomy, has anti-fibrotic properties, and benefits from sustained drainage efficacy over time due to bio-integration of surrounding tissues into the material. A natural flow speed results, which reduces the incidence of fibrosis, minimises scarring, and increases implant durability. Recently, the FDA approved the commencement of the STAR-V pivotal trial which will evaluate MINIjectTM in over 350 patients.